Rubicon Research Limited (RUBICON) — Announcement | 14 August 2026 (2 announcements)

14 August 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

1Announcement Neutral📄 PDF

📢 Key Event

Rubicon Research Limited showcased Q1 FY27 results and strategic acquisition plans during its August 14, 2026 investor presentation.

🔮 What's Next

US manufacturing facility to commence operations in CY2027 after QMS implementation and capex

💡 Investor Takeaway

Shareholders gain exposure to high-growth specialty pharmaceuticals with expanding US manufacturing capabilities and proven regulatory compliance.

Rubicon Research Limited presented its Q1 FY27 investor presentation on August 14, 2026, highlighting 51.6% YoY revenue growth to [amount not verified], robust EBITDA of [amount not verified], and 24.2% operating margin expansion. The filing details strategic acquisitions including Validus Pharmaceuticals and InvaTech Pharma Solutions LLC, with plans to commence US manufacturing in CY2027. Key operational updates include five USFDA-approved nasal spray products, zero FDA observations across recent inspections, and significant R&D productivity gains.

2Announcement Neutral📄 PDF

📢 Key Event

Audio recording of earnings conference call released

💡 Investor Takeaway

Shareholders can now listen to the full earnings discussion to assess performance and outlook.

Rubicon Research Limited announced that the audio recording of its earnings conference call for the quarter ended June 30, 2026 is now available on its website, providing investors access to the latest financial discussion.

📊 Stock Analysis — RUBICON ✨ Ask AI About This

About Rubicon Research Limited (RUBICON)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹26,694.43 CrP/E: 90.9ROE: 22.4%ROCE: 26.6%Div Yield: 0.09%

View full RUBICON stock details →

📡 Get AI alerts when RUBICON files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RUBICON — Free

💡 Ask AI about this filing

"How will the InvaTech acquisition impact profitability timelines?""What is the valuation multiple for the new US manufacturing facility?""When will the first products be manufactured at the New Jersey site?"

Ask AI Free →

📊 More RUBICON filings

Announcement — 28 September 2026Rubicon Research Limited announced that its trading window will close on October 1, 2026, ahead of t...
🔴 Insider Trading — 29 August 2026Rubicon Research disclosed a promoter stake sale of 1.4 million shares to General Atlantic Singapore...
🔴 Insider Trading — 27 August 2026Rubicon Research Limited disclosed that General Atlantic Singapore RR Pte. Ltd., its promoter, sold ...
🟡 Board Meeting — 26 August 2026Rubicon Research Limited held its 27th Annual General Meeting on August 26, 2026, via video conferen...
🔴 Financial Results — 19 August 2026Rubicon Research reported Q1 FY27 revenue of **₹534 crores**, up **51% YoY**, with EBITDA at **₹131 ...

See all RUBICON filings →

🔥 Also filed on 14 August 2026

CEIGALLCeigall India LimitedFinancial Results MAHAPEXLTDMaha Rashtra Apex Corporation LimitedCorporate Action SAATVIKGLSaatvik Green Energy LimitedFinancial Results LIBASLibas Consumer Products LimitedCorporate Action GENUSPOWERGenus Power Infrastructures LimitedFinancial Results LUXINDLux Industries LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when RUBICON files new disclosures

Track RUBICON filings, board meetings, and corporate actions. Free email alerts at 5 PM.